SCHEMBL14950779

SCHEMBL14950779

COC(=O)N[C@@H](C(=O)O)[C@@H]1CCO[C@H](C2CC2)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17068306 1.00 — —
SCHEMBL18467421 1.00 — —
SCHEMBL14950778 1.00 — —
SCHEMBL17068305 1.00 — —
SCHEMBL18467490 0.84 L3MBTL1 (0.33) —
SCHEMBL18467489 0.84 L3MBTL1 (0.33) —
SCHEMBL18467491 0.84 L3MBTL1 (0.33) —
SCHEMBL14950801 0.84 L3MBTL1 (0.33) —
SCHEMBL14950802 0.84 L3MBTL1 (0.33) —
SCHEMBL10210058 0.83 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9546160-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-01-17 — — US disclosed
US-20160338999-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2016-11-24 — — US disclosed
US-20130121957-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2013-05-16 — — US disclosed
Send feedback